Medcap AbOMXSTO: MCAP

MCAP: Q3 2025 delivered 21% sales growth, 32% EBITA growth, and strong segment performance

· Issued by Medcap AB

Q3 2025 saw 21% sales growth and 32% adjusted EBITA growth, with strong results across all segments and a robust balance sheet. Recent acquisitions and a positive M&A outlook support continued expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Medcap Ab

All Medcap Ab news releases